Mon, September 27, 2010
[ Mon, Sep 27th 2010 ] - Market Wire
Wellstar Announces New Website
Sun, September 26, 2010
Sat, September 25, 2010
Fri, September 24, 2010
Thu, September 23, 2010
Wed, September 22, 2010
Tue, September 21, 2010
Mon, September 20, 2010
Fri, September 17, 2010
Thu, September 16, 2010
Wed, September 15, 2010
[ Wed, Sep 15th 2010 ] - Market Wire
Qtrax Beta Available in India
Tue, September 14, 2010
Mon, September 13, 2010
Sun, September 12, 2010
Fri, September 10, 2010
Thu, September 9, 2010
Wed, September 8, 2010
Tue, September 7, 2010
Sat, September 4, 2010
[ Sat, Sep 04th 2010 ] - Market Wire
Transdel Pharmaceuticals
Fri, September 3, 2010
[ Fri, Sep 03rd 2010 ] - Market Wire
Transdel Pharmaceuticals

Alnylam to Webcast Presentation at UBS Global Life Sciences Conference


//health-fitness.news-articles.net/content/2010/ .. tion-at-ubs-global-life-sciences-conference.html
Published in Health and Fitness on Tuesday, September 14th 2010 at 13:10 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the UBS Global Life Sciences Conference on Tuesday, September 21 at 3:30 p.m. ET at The Grand Hyatt New York.

A live audio webcast of the presentation will be available on the aInvestorsa section of the companya™s website, [ www.alnylam.com ]. A replay of the presentation will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the worlda™s top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics for the treatment of a wide range of disease areas, including respiratory syncytial virus (RSV), liver cancers, TTR-mediated amyloidosis (ATTR), hypercholesterolemia, and Huntingtona™s disease. In addition, Alnylam formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies. The companya™s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. Alnylam and Isis are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA-based therapeutics. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit [ www.alnylam.com ].


Publication Contributing Sources